NCT04630379 is a NA clinical trial of Palliative Therapy in Glioblastoma, sponsored by Mayo Clinic.

Who is sponsoring NCT04630379?

NCT04630379 is sponsored by Mayo Clinic.

What drugs are being tested in NCT04630379?

Interventions in NCT04630379: Palliative Therapy, Quality-of-Life Assessment, Supportive Care, Survey Administration.

What condition does NCT04630379 study?

NCT04630379 studies Glioblastoma, Malignant Glioma, WHO Grade III Glioma.

Is NCT04630379 still recruiting?

NCT04630379 is currently completed. Last updated 20 March 2023.

Last reviewed 2023-03-20 · How we verify

NCT04630379

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers

Completed NA Last updated 20 March 2023

What this trial tests

NA trial testing Palliative Therapy in Glioblastoma in 16 participants. Completed in 31 August 2020.

Timeline

13 June 2018

Primary endpoint
13 June 2019

31 August 2020

Quick facts

Lead sponsor	Mayo Clinic
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	16
Start date	13 June 2018
Primary completion	13 June 2019
Estimated completion	31 August 2020
Sites	1 location across United States

Drugs / interventions tested

Palliative Therapy
Quality-of-Life Assessment
Supportive Care — full drug profile →
Survey Administration

Conditions studied

Glioblastoma — all drugs for Glioblastoma →
Malignant Glioma — all drugs for Malignant Glioma →
WHO Grade III Glioma — all drugs for WHO Grade III Glioma →

Sponsor

Mayo Clinic

Who can join

18 and older, any sex, with Glioblastoma or Malignant Glioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial assesses the quality of life in patients with high grade glioma and their caregivers using a questionnaire called the Beacon Patient Related Outcomes Quality of Life (PROQOL). Knowledge gained from this trial may help researchers find out if early integration of palliative care will lead to improvement in quality of life for both patients and caregivers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

How much time do we have? Longitudinal perception of prognosis in newly-diagnosed high grade glioma patients and caregivers compared to clinicians.
Sharma A, Fruth B, Barrera C, Farfour HN, et al · · 2021 · cited 18× · PMID 33486637 · DOI 10.1007/s11060-021-03700-2

Verify or expand the search:

Other trials of Palliative Therapy

Trials testing the same drug.

NCT06063603 — Evaluation of a Pain Management Intervention Preparatory to a Future Pragmatic Trial, ASCENT Study · NA · completed
NCT05338905 — Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Metastatic H · NA · active not recruiting
NCT04989556 — Technology-Enhanced Palliative Care for Advanced Cancer Patients · NA · active not recruiting
NCT04662645 — Embedded Palliative Care in Managing Symptoms in Participants With Recurrent Stage III-IV Thoracic Malignancies and Thei · NA · completed

Other recruiting trials for Glioblastoma

Currently open trials in the same condition.

NCT07284069 — Senicapoc and Perampanel for Newly Diagnosed Glioblastoma · EARLY_PHASE1 · recruiting
NCT05653635 — Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study · Phase 2 · recruiting
NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Mayo Clinic trials

Trials by the same sponsor.

NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04630379 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
Last refreshed: 20 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04630379.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing